The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...
Investing in dividend-paying stocks is one of numerous approaches that can help you maximize your portfolio growth, and ...
The S&P 500 Dividend Aristocrats tracks companies in the index that have raised dividends every year for at least 25 straight ...
Objectives The European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of systemic lupus erythematosus (SLE) and lupus nephritis provide important guidance for ...
Objective This study aimed to evaluate the prevalence and predictors of cardiovascular disease (CVD), chronic kidney disease ...
Dr Mark Kris breaks down the lazertinib-amivantamab data, noting that the combo shows benefit but fails to address key ...
SurvivorNet on MSN
Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients
Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
About one in nine adults suffer from chronic insomnia and its residual effects like drowsiness, cognitive issues, and ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...
The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Genomics-driven cancer diagnostics are ...
Some dietary supplements may help naturally boost GLP-1, but more research is needed to better understand their potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback